SAN DIEGO--(BUSINESS WIRE)--Sept. 7, 2007--Illumina (NASDAQ:ILMN)announced today that SNP Genetics, a leading company in the Koreangenetics community is the first genetics service provider in Asia toreceive Illumina Certified Service Provider (CSPro) certification forInfinium(R) Genotyping. SNP Genetics has partnered with Illumina toprovide its customers with unique, high-value genotyping services. SNPGenetics is a bio-venture company applying its discoveries in humangenetics to the development of diagnostic markers for common diseases.Using a population approach with state-of-the-art technologies andresources, SNP Genetics can efficiently conduct population- andgenome-wide scans for the key genetic factors involved in any commondisease.
"We chose Illumina because their data quality is the best in theindustry, and through our genotyping services we want to offer thislevel of quality to our customers," said Hyoung Doo Shin, Ph.D.,D.V.M, Chief Executive Officer of SNP Genetics. "This achievementunderscores SNP Genetics' commitment to providing the best and mostcomprehensive genotyping and analytical solutions, speeding thediscovery process for our customers."
"Interest in Illumina CSPro has continued to grow because of thepartnership opportunity it offers. Service providers worldwiderecognize the value that Illumina technology can bring to theircustomers and they understand that the program can be a key factor intheir success," said Karen Possemato, Director of Corporate Marketingfor Illumina. "Now that SNP Genetics is a partner, we are excited towork with them to make it easier for customers in Asia to access thepower of Illumina's genotyping products for their studies."
About Illumina CSPro
Illumina CSPro is a collaborative service provider partnershipdedicated to ensuring the delivery of the highest-quality dataavailable for genetic analysis applications. Illumina CSPros undergo arigorous two-phase certification process that includes minimum datageneration requirements, data certification and on-site audit of thefacility and processes. For more information about the CSPro program,please visit www.illumina.com/cspro.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integratedsystems for the analysis of genetic variation and biological function.Using our proprietary technologies, we provide a comprehensive line ofproducts and services that currently serve the sequencing, genotyping,and gene expression markets, and we expect to enter the market formolecular diagnostics. Our customers include leading genomic researchcenters, pharmaceutical companies, academic institutions, clinicalresearch organizations, and biotechnology companies. Our tools provideresearchers around the world with the performance, throughput, costeffectiveness, and flexibility necessary to perform the billions ofgenetic tests needed to extract valuable medical information fromadvances in genomics and proteomics. We believe this information willenable researchers to correlate genetic variation and biologicalfunction, which will enhance drug discovery and clinical research,allow diseases to be detected earlier, and permit better choices ofdrugs for individual patients.
"Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: this release may contain forward-lookingstatements that involve risks and uncertainties. Among the importantfactors that could cause actual results to differ materially fromthose in any forward-looking statements are the costs and outcome ofIllumina's litigation with Affymetrix and our ability (i) to integrateeffectively our recent acquisition of Solexa, Inc., (ii) to developand commercialize further our BeadArray(TM), VeraCode(TM) andSolexa(R) technologies and to deploy new gene expression andgenotyping products and applications for our technology platforms,(iii) to manufacture robust micro arrays and Oligator(R)oligonucleotides, (iv) to integrate and scale our VeraCode technology,(v) to scale further oligo synthesis output and technology to satisfymarket demand derived from our collaboration with Invitrogen, togetherwith other factors detailed in our filings with the Securities andExchange Commission including our recent filings on Forms 10-K and10-Q or in information disclosed in public conference calls, the dateand time of which are released beforehand. We disclaim any intent orobligation to update these forward-looking statements beyond the dateof this release.
CONTACT: Illumina
Media Contact:
Maurissa Bornstein, Public Relations Manager
858-332-4055
mbornstein@illumina.com
Investor Contact:
Peter J. Fromen, Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
SOURCE: Illumina